{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:51:52Z","timestamp":1788580312307,"version":"build-2803163510"},"reference-count":131,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:p>Degenerative aortic stenosis is a growing clinical problem owing to the high incidence in an aging population and its significant morbidity and mortality. Currently, aortic valve replacement remains the only treatment. Despite promising observational data, pharmacological management to slow or halt progression of aortic stenosis has remained elusive. Nevertheless, with a greater understanding of the mechanisms which underpin aortic stenosis, research has begun to explore novel treatment strategies. This review will explore the historical agents used to manage aortic stenosis and the emerging agents that are currently under investigation.<\/jats:p>","DOI":"10.1097\/crd.0000000000000528","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T15:02:54Z","timestamp":1679670174000},"page":"473-482","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Medical Therapy to Prevent or Slow Progression of Aortic Stenosis: Current Evidence and Future Directions"],"prefix":"10.1097","volume":"32","author":[{"given":"Travis","family":"Chong","sequence":"first","affiliation":[{"name":"Department of Cardiology, Fiona Stanley Hospital, Perth, Australia"},{"name":"Harry Perkins Institute of Medical Research, Perth, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick S. R.","family":"Lan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fiona Stanley Hospital, Perth, Australia"},{"name":"Harry Perkins Institute of Medical Research, Perth, Australia"},{"name":"Internal Medicine, Medical School, The University of Western Australia, Perth, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Courtney","sequence":"additional","affiliation":[{"name":"Internal Medicine, Medical School, The University of Western Australia, Perth, Australia"},{"name":"Department of Cardiology, Royal Perth Hospital, Perth, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"He","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fiona Stanley Hospital, Perth, Australia"},{"name":"Harry Perkins Institute of Medical Research, Perth, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoff","family":"Strange","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Notre Dame, Fremantle, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Playford","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Notre Dame, Fremantle, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish","family":"Dwivedi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fiona Stanley Hospital, Perth, Australia"},{"name":"Harry Perkins Institute of Medical Research, Perth, Australia"},{"name":"Internal Medicine, Medical School, The University of Western Australia, Perth, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham S.","family":"Hillis","sequence":"additional","affiliation":[{"name":"Internal Medicine, Medical School, The University of Western Australia, Perth, Australia"},{"name":"Department of Cardiology, Royal Perth Hospital, Perth, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Rahman","family":"Ihdayhid","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fiona Stanley Hospital, Perth, Australia"},{"name":"Harry Perkins Institute of Medical Research, Perth, Australia"},{"name":"Curtin Medical School, Curtin University, Perth, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,3,24]]},"reference":[{"key":"R1-20250619","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.jacc.2019.08.004","article-title":"Poor long-term survival in patients with moderate aortic stenosis.","volume":"74","author":"Strange","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R2-20250619","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S2666-7568(22)00168-4","article-title":"Counting the cost of premature mortality with progressively worse aortic stenosis in Australia: a clinical cohort study.","volume":"3","author":"Stewart","year":"2022","journal-title":"Lancet Healthy Longev"},{"key":"R3-20250619","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1136\/heartjnl-2021-319697","article-title":"Incident aortic stenosis in 49 449 men and 42 229 women investigated with routine echocardiography.","volume":"108","author":"Stewart","year":"2022","journal-title":"Heart"},{"key":"R4-20250619","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1001\/jamacardio.2021.3718","article-title":"Association of mortality with aortic stenosis severity in outpatients: results from the VALVENOR study.","volume":"6","author":"Coisne","year":"2021","journal-title":"JAMA Cardiol"},{"key":"R5-20250619","doi-asserted-by":"crossref","first-page":"e0268580","DOI":"10.1371\/journal.pone.0268580","article-title":"Increasing risk of mortality across the spectrum of aortic stenosis is independent of comorbidity & treatment: an international, parallel cohort study of 248,464 patients.","volume":"17","author":"Strom","year":"2022","journal-title":"PLoS One"},{"key":"R6-20250619","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","article-title":"2021 ESC\/EACTS guidelines for the management of valvular heart disease.","volume":"43","author":"Vahanian","year":"2022","journal-title":"Eur Heart J"},{"key":"R7-20250619","first-page":"72","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: a report of the American college of cardiology. American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"143","author":"Otto","year":"2020","journal-title":"Circulation"},{"key":"R8-20250619","first-page":"1783","article-title":"Calcific aortic valve disease: not simply a degenerative process a review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group.","volume":"124","author":"Rahamannan","year":"2011","journal-title":"Circulation"},{"key":"R9-20250619","doi-asserted-by":"crossref","first-page":"e006339.","DOI":"10.1161\/JAHA.117.006339","article-title":"Valve interstitial cells: the key to understanding the pathophysiology of heart valve calcification.","volume":"14:6","author":"Rutkovskiy","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"R10-20250619","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1161\/ATVBAHA.114.302523","article-title":"Calcific aortic valve disease: a consensus summary from the Alliance of Investigators on Calcific Aortic Valve Disease.","volume":"34","author":"Yutzey","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R11-20250619","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1161\/01.CIR.90.2.844","article-title":"Characterization of the early lesion of \u201cdegenerative\u201d valvular aortic stenosis. Histological and immunohistochemical studies.","volume":"90","author":"Otto","year":"1994","journal-title":"Circulation"},{"key":"R12-20250619","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccl.2019.09.010","article-title":"Pathophysiology of aortic stenosis and future perspectives for medical therapy.","volume":"38","author":"Zheng","year":"2020","journal-title":"Cardiol Clin"},{"key":"R13-20250619","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1088\/0143-0815\/10\/1\/002","article-title":"Experimental fluid dynamics of aortic stenosis in a model of the human aorta.","volume":"10","author":"Yearwood","year":"1989","journal-title":"Clin Phys Physiol Meas"},{"key":"R14-20250619","doi-asserted-by":"crossref","first-page":"e65810","DOI":"10.1371\/journal.pone.0065810","article-title":"Modified lipoprotein-derived lipid particles accumulate in human stenotic aortic valves.","volume":"8","author":"Lehti","year":"2013","journal-title":"PLoS One"},{"key":"R15-20250619","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jacc.2013.05.105","article-title":"Elevated expression of lipoprotein-associated phospholipase A2 in calcific aortic valve disease: implications for valve mineralization.","volume":"63","author":"Mahmut","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R16-20250619","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jacc.2008.05.043","article-title":"Dysregulation of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvular stenosis in humans.","volume":"52","author":"Miller","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R17-20250619","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1101\/gad.276304","article-title":"Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation.","volume":"18","author":"Timmerman","year":"2004","journal-title":"Genes Dev"},{"key":"R18-20250619","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1253\/circj.CJ-11-0395","article-title":"Cardiovascular calcification: an inflammatory disease.","volume":"75","author":"New","year":"2011","journal-title":"Circ J"},{"key":"R19-20250619","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1016\/j.jacc.2007.07.064","article-title":"Clinical factors, but not C-reactive protein, predict progression of calcific aortic-valve disease: the Cardiovascular Health Study.","volume":"50","author":"Novaro","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R20-20250619","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.amjcard.2009.10.071","article-title":"Incidence and progression of aortic valve calcium in the Multi-ethnic Study of Atherosclerosis (MESA).","volume":"105","author":"Owens","year":"2010","journal-title":"Am J Cardiol"},{"key":"R21-20250619","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1016\/j.jacc.2009.12.068","article-title":"Bicuspid aortic valve disease.","volume":"55","author":"Siu","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R22-20250619","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.cjca.2014.04.026","article-title":"Left ventricular remodelling in aortic stenosis.","volume":"30","author":"Rassi","year":"2014","journal-title":"Can J Cardiol"},{"key":"R23-20250619","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0002-9149(76)80015-X","article-title":"Left ventricular compliance: mechanisms and clinical implications.","volume":"38","author":"Gaasch","year":"1976","journal-title":"Am J Cardiol"},{"key":"R24-20250619","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.jcin.2020.03.011","article-title":"Left Ventricular hypertrophy and clinical outcomes over 5 years after TAVR: an analysis of the PARTNER trials and registries.","volume":"13","author":"Gonzales","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"R25-20250619","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1016\/j.jacc.2020.03.042","article-title":"Regression of left ventricular mass after transcatheter aortic valve replacement: the PARTNER trials and registries.","volume":"75","author":"Chau","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"R26-20250619","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.jcmg.2019.01.045","article-title":"Why and how to measure aortic valve calcification in patients with aortic stenosis.","volume":"12","author":"Pawade","year":"2019","journal-title":"J Am Coll Cardiol Img"},{"key":"R27-20250619","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jcmg.2018.10.023","article-title":"The role of imaging in measuring disease progression and assessing novel therapies in aortic stenosis.","volume":"12","author":"Doris","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"R28-20250619","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1056\/NEJMoa043876","article-title":"A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis.","volume":"352","author":"Cowell","year":"2005","journal-title":"N Engl J Med"},{"key":"R29-20250619","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa0804602","article-title":"Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.","volume":"359","author":"Rosseb\u00f8","year":"2008","journal-title":"N Engl J Med"},{"key":"R30-20250619","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1161\/CIRCULATIONAHA.109.900027","article-title":"Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial.","volume":"121","author":"Chan","year":"2010","journal-title":"Circulation"},{"key":"R31-20250619","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.amjcard.2011.03.032","article-title":"Effects of rosuvastatin on progression of stenosis in adult patients with congenital aortic stenosis (PROCAS Trial).","volume":"108","author":"Van der Linde","year":"2011","journal-title":"Am J Cardiol"},{"key":"R32-20250619","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1161\/01.CIR.0000140723.15274.53","article-title":"Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis.","volume":"110","author":"Rosenhek","year":"2004","journal-title":"Circulation"},{"key":"R33-20250619","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1001\/archinte.165.8.858","article-title":"Angiotensin-converting enzyme inhibitors and change in aortic valve calcium.","volume":"165","author":"O\u2019Brien","year":"2005","journal-title":"Arch Intern Med"},{"key":"R34-20250619","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ijcard.2014.06.013","article-title":"Renin-angiotensin system inhibition is not associated with increased sudden cardiac death, cardiovascular.","volume":"175","author":"Bang","year":"2014","journal-title":"Int J Cardiol"},{"key":"R35-20250619","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/ehjci\/jev043","article-title":"A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial).","volume":"16","author":"Bull","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"R36-20250619","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jacc.2011.01.063","article-title":"Impact of renin-angiotensin system blockade therapy on outcome in aortic stenosis.","volume":"58","author":"Nadir","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"R37-20250619","doi-asserted-by":"crossref","first-page":"7401766","DOI":"10.1016\/j.ahj.2003.10.017","article-title":"Safety and efficacy of angiotensin-converting enzyme inhibitors in symptomatic severe aortic stenosis: Symptomatic Cardiac Obstruction-Pilot Study of Enalapril in Aortic Stenosis (SCOPE-AS).","volume":"147","author":"Chockalingam","year":"2004","journal-title":"Am Heart J"},{"key":"R38-20250619","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ahj.2013.11.002","article-title":"Short-term hemodynamic effect of angiotensin-converting enzyme inhibition in patients with severe aortic stenosis: a placebo-controlled, randomized study.","volume":"167","author":"Dalsgaard","year":"2014","journal-title":"Am Heart J"},{"key":"R39-20250619","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1111\/j.1365-2362.2011.02522.x","article-title":"Angiotensin receptor blockers are associated with a lower remodelling score of stenotic aortic valves.","volume":"41","author":"C\u00f4t\u00e9","year":"2011","journal-title":"Eur J Clin Inveset"},{"key":"R40-20250619","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000321418","article-title":"Bisphosphonates in calcific aortic stenosis: association with slower progression in mild disease--a pilot retrospective study.","volume":"117","author":"Sterbakova","year":"2010","journal-title":"Cardiology"},{"key":"R41-20250619","first-page":"65","article-title":"Alendronate slows down aortic stenosis progression in osteoporotic patients: an observational prospective study.","volume":"30","author":"Alishiri","year":"2020","journal-title":"J Res Med Sci"},{"key":"R42-20250619","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.jacc.2010.05.050","article-title":"Bisphosphonate use and prevalence of valvular and vascular calcification in women: MESA (The Multi-Ethnic Study of Atherosclerosis).","volume":"56","author":"Elmariah","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R43-20250619","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1161\/CIRCULATIONAHA.121.053708","article-title":"Effect of denosumab or alendronic acid on the progression of aortic stenosis: a double-blind randomized controlled trial.","volume":"143","author":"Pawade","year":"2021","journal-title":"Circulation"},{"key":"R44-20250619","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1161\/CIRCULATIONAHA.116.027011","article-title":"Slower progress of aortic valve calcification with vitamin K supplementation: results from a prospective interventional proof-of-concept study.","volume":"135","author":"Brandenburg","year":"2017","journal-title":"Circulation"},{"key":"R45-20250619","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.121.057008","article-title":"Vitamin K2 and D in patients with aortic valve calcification: a randomized double-blinded clinical trial.","volume":"145","author":"Diederichsen","year":"2022","journal-title":"Circulation"},{"key":"R46-20250619","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/ehjci\/jew013","article-title":"Systolic hypertension and progression of aortic valve calcification in patients with aortic stenosis: results from the PROGRESSA study.","volume":"18","author":"Tastet","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"R47-20250619","doi-asserted-by":"crossref","first-page":"e006557","DOI":"10.1161\/CIRCIMAGING.117.006557","article-title":"Metoprolol reduces hemodynamic and metabolic overload in asymptomatic aortic valve stenosis patients: a randomized trial.","volume":"10","author":"Hansson","year":"2017","journal-title":"Circ Cardiovasc Imaging"},{"key":"R48-20250619","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1161\/CIRCULATIONAHA.111.081125","article-title":"Effects of phosphodiesterase type 5 inhibition on systemic and pulmonary hemodynamics and ventricular function in patients with severe symptomatic aortic stenosis.","volume":"125","author":"Lindman","year":"2012","journal-title":"Circulation"},{"key":"R49-20250619","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1161\/hc4101.097527","article-title":"Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors.","volume":"04","author":"Pohle","year":"2001","journal-title":"Circulation"},{"key":"R50-20250619","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/jamacardio.2019.3903","article-title":"Association of low-density lipoprotein cholesterol with risk of aortic valve stenosis in familial hypercholesterolemia.","volume":"4","author":"Mundal","year":"2019","journal-title":"JAMA Cardiol"},{"key":"R51-20250619","doi-asserted-by":"crossref","first-page":"e002711","DOI":"10.1161\/CIRCGEN.119.002711","article-title":"Genetic determinants of lipids and cardiovascular disease outcomes: a wide-angled mendelian randomization investigation.","volume":"12","author":"Allara","year":"2019","journal-title":"Circ Genom Precis Med"},{"key":"R52-20250619","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1161\/hc4301.098249","article-title":"Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis.","volume":"104","author":"Novaro","year":"2001","journal-title":"Circulation"},{"key":"R53-20250619","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S0140-6736(02)08161-8","article-title":"HMG CoA reductase inhibitor (statin) and aortic valve calcium.","volume":"359","author":"Shavelle","year":"2002","journal-title":"Lancet"},{"key":"R54-20250619","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/S0735-1097(02)02496-8","article-title":"Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community.","volume":"40","author":"Bellamy","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"R55-20250619","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jacc.2006.07.072","article-title":"Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis.","volume":"49","author":"Moura","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R56-20250619","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1016\/j.jacc.2009.01.064","article-title":"Hydroxymethylglutaryl coenzyme-a reductase inhibitors delay the progression of rheumatic aortic valve stenosis a long-term echocardiographic study.","volume":"53","author":"Antonini-Canterin","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R57-20250619","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.amjcard.2003.08.066","article-title":"Effect of statins on the progression of bioprosthetic aortic valve degeneration.","volume":"92","author":"Antonini-Canterin","year":"2003","journal-title":"Am J Cardiol"},{"key":"R58-20250619","first-page":"Cd009571","article-title":"Statins for aortic valve stenosis.","volume":"9","author":"Thiago","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"R59-20250619","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.amjcard.2014.01.414","article-title":"Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL).","volume":"113","author":"Arsenault","year":"2014","journal-title":"Am J Cardiol"},{"key":"R60-20250619","first-page":"35","article-title":"2020 ACC\/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"143","author":"Otto","year":"2021","journal-title":"Circulation"},{"key":"R61-20250619","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1161\/HYPERTENSIONAHA.112.202697","article-title":"Higher ambulatory blood pressure is associated with aortic valve calcification in the elderly: a population-based study.","volume":"61","author":"Iwata","year":"2013","journal-title":"Hypertension"},{"key":"R62-20250619","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jacc.2012.03.052","article-title":"Impact of metabolic syndrome on progression of aortic stenosis: influence of age and statin therapy.","volume":"60","author":"Capoulade","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R63-20250619","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jacc.2004.10.081","article-title":"Reduced systemic arterial compliance impacts significantly on left ventricular afterload and function in aortic stenosis: implications for diagnosis and treatment.","volume":"46","author":"Briand","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R64-20250619","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1136\/hrt.39.6.651","article-title":"Effects of isometric exercise and increased arterial impedance on left ventricular function in severe aortic valvular stenosis.","volume":"39","author":"Awan","year":"1977","journal-title":"Br Heart J"},{"key":"R65-20250619","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1161\/CIRCRESAHA.111.300084","article-title":"Current management of calcific aortic stenosis.","volume":"113","author":"Lindman","year":"2013","journal-title":"Circ Res"},{"key":"R66-20250619","doi-asserted-by":"crossref","first-page":"e003644","DOI":"10.1161\/CIRCIMAGING.115.003644","article-title":"Relation of left ventricular mass to prognosis in initially asymptomatic mild to moderate aortic valve stenosis.","volume":"8","author":"Gerdts","year":"2015","journal-title":"Circ Cardiovasc Imaging"},{"key":"R67-20250619","doi-asserted-by":"crossref","first-page":"e45570","DOI":"10.1371\/journal.pone.0045570","article-title":"Association of left ventricular mass with all-cause mortality, myocardial infarction and stroke.","volume":"7","author":"Bouzas-Mosquera","year":"2012","journal-title":"PLoS One"},{"key":"R68-20250619","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1056\/NEJM199005313222203","article-title":"Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study.","volume":"322","author":"Levy","year":"1990","journal-title":"N Engl J Med"},{"key":"R69-20250619","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1161\/CIRCULATIONAHA.116.023997","article-title":"Medical treatment of aortic stenosis.","volume":"134","author":"Marquis-Gravel","year":"2016","journal-title":"Circulation"},{"key":"R70-20250619","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1476-5381.2010.01084.x","article-title":"Ramipril retards development of aortic valve stenosis in a rabbit model: mechanistic considerations.","volume":"162","author":"Ngo","year":"2011","journal-title":"Br J Pharmacol"},{"key":"R71-20250619","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/heartjnl-2017-311738","article-title":"Renin-angiotensin system blockade therapy after transcatheter aortic valve implantation.","volume":"104","author":"Ochiai","year":"2018","journal-title":"Heart"},{"key":"R72-20250619","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1001\/jama.2018.18077","article-title":"Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter aortic valve replacement.","volume":"320","author":"Inohara","year":"2018","journal-title":"JAMA"},{"key":"R73-20250619","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.jacc.2004.07.054","article-title":"Induction of local angiotensin II-producing systems in stenotic aortic valves.","volume":"44","author":"Helske","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"R74-20250619","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1152\/ajpcell.00287.2006","article-title":"Angiotensin II cell signalling: physiological and pathological effects in the cardiovascular system.","volume":"292","author":"Mehta","year":"2007","journal-title":"Am J Physiol Cell Physiol"},{"key":"R77-20250619","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jacl.2019.04.010","article-title":"Use of Lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association.","volume":"13","author":"Wilson","year":"2019","journal-title":"J Clin Lipidol"},{"key":"R78-20250619","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction.","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"R79-20250619","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1093\/eurheartj\/ehx166","article-title":"Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium.","volume":"38","author":"Waldeyer","year":"2017","journal-title":"Eur Heart J"},{"key":"R80-20250619","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population.","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R81-20250619","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCGENETICS.113.000400","article-title":"Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort.","volume":"7","author":"Arsenault","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"key":"R82-20250619","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1001\/jamacardio.2018.3798","article-title":"Association of mild to moderate aortic valve stenosis progression with higher lipoprotein(a) and oxidized phospholipid levels: secondary analysis of a randomized clinical trial.","volume":"3","author":"Capoulade","year":"2018","journal-title":"JAMA Cardiol"},{"key":"R83-20250619","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels.","volume":"41","author":"Tsimikas","year":"2019","journal-title":"Eur Heart J"},{"key":"R84-20250619","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1016\/j.jacc.2016.10.033","article-title":"Phenotypic characterization of genetically lowered human lipoprotein(a) levels.","volume":"68","author":"Emdin","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"R85-20250619","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.metabol.2016.08.007","article-title":"Effect of extended-release niacin on plasma lipoprotein(a) levels: a systematic review and meta-analysis of randomized placebo-controlled trials.","volume":"65","author":"Sahebkar","year":"2016","journal-title":"Metabolism"},{"key":"R86-20250619","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease.","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"key":"R87-20250619","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome.","volume":"75","author":"Bittner","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"R88-20250619","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk.","volume":"139","author":"O\u2019Donoghue","year":"2019","journal-title":"Circulation"},{"key":"R89-20250619","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1210\/jc.2016-1206","article-title":"PCSK9 R46L loss-of-function mutation reduces lipoprotein(a), LDL cholesterol, and risk of aortic valve stenosis.","volume":"101","author":"Langsted","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"R90-20250619","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol.","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"R91-20250619","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1172\/JCI116391","article-title":"Bone morphogenetic protein expression in human atherosclerotic lesions.","volume":"91","author":"Bostr\u00f6m","year":"1993","journal-title":"J Clin Invest"},{"key":"R92-20250619","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.yjmcc.2003.09.015","article-title":"Receptor activator of nuclear factor \u03baB ligand and osteoprotegerin regulate aortic valve calcification.","volume":"36","author":"Kaden","year":"2004","journal-title":"J Mol Cell Cardiol"},{"key":"R93-20250619","doi-asserted-by":"crossref","first-page":"e65201","DOI":"10.1371\/journal.pone.0065201","article-title":"Osteoprotegerin inhibits aortic valve calcification and preserves valve function in hypercholesterolemic mice.","volume":"8","author":"Weiss","year":"2013","journal-title":"PLoS One"},{"key":"R94-20250619","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1083\/jcb.200402046","article-title":"Extracellular matrix mineralization is regulated locally; different roles of two Gla-containing proteins.","volume":"165","author":"Murshed","year":"2004","journal-title":"J Cell Bio"},{"key":"R95-20250619","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.molmed.2012.12.008","article-title":"Vitamin K-dependent carboxylation of matrix Gla-protein: a crucial switch to control ectopic mineralization.","volume":"19","author":"Schurgers","year":"2013","journal-title":"Trends Mol Med"},{"key":"R96-20250619","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jss.2015.04.076","article-title":"Matrix Gla protein regulates calcification of the aortic valve.","volume":"199","author":"Venardos","year":"2015","journal-title":"J Surg Res"},{"key":"R97-20250619","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/ehjci\/jeaa065","article-title":"Association of aortic valve calcification and vitamin K antagonist treatment.","volume":"21","author":"S\u00f8nderskov","year":"2020","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"R98-20250619","doi-asserted-by":"crossref","first-page":"e002665","DOI":"10.1161\/JAHA.115.002665","article-title":"Increased peripheral arterial calcification in patients receiving warfarin.","volume":"5","author":"Han","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"R99-20250619","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3945\/ajcn.116.137281","article-title":"Dietary soy and natto intake and cardiovascular disease mortality in Japanese adults: the Takayama study.","volume":"105","author":"Nagata","year":"2017","journal-title":"Am J Clin Nutr"},{"key":"R100-20250619","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.atherosclerosis.2008.07.010","article-title":"Grobbee de and van der Schouw YT. high dietary menaquinone intake is associated with reduced coronary calcification.","volume":"203","author":"Beulens","year":"2009","journal-title":"Atherosclerosis"},{"key":"R101-20250619","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1093\/jn\/134.11.3100","article-title":"Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam study.","volume":"134","author":"Geleijnse","year":"2004","journal-title":"J Nutr"},{"key":"R104-20250619","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/nrcardio.2010.67","article-title":"Transthyretin-related amyloidoses and the heart: a clinical overview.","volume":"7","author":"Rapezzi","year":"2010","journal-title":"Nat Rev Cardiol"},{"key":"R105-20250619","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement.","volume":"38","author":"Castano","year":"2017","journal-title":"Eur Heart J"},{"key":"R106-20250619","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1093\/eurheartj\/ehaa170","article-title":"Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for trans-catheter aortic valve implantation.","volume":"41","author":"Scully","year":"2020","journal-title":"Eur Heart J"},{"key":"R107-20250619","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/ejhf.1974","article-title":"Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis.","volume":"23","author":"Rosenblum","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"R108-20250619","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jacc.2020.11.006","article-title":"Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis.","volume":"77","author":"Nitsche","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"R110-20250619","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/j.athoracsur.2006.07.043","article-title":"Malignant natural history of asymptomatic severe aortic stenosis: benefit of aortic valve replacement.","volume":"82","author":"Pai","year":"2006","journal-title":"Ann Thorac Surg"},{"key":"R111-20250619","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/HYPERTENSIONAHA.112.194878","article-title":"Hypertension in aortic stenosis: implications for left ventricular structure and cardiovascular events.","volume":"60","author":"Rieck","year":"2012","journal-title":"Hypertension"},{"key":"R112-20250619","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jacc.2007.04.079","article-title":"Resting heart rate in cardiovascular disease.","volume":"50","author":"Fox","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R113-20250619","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.ahj.2009.12.029","article-title":"Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women.","volume":"159","author":"Cooney","year":"2010","journal-title":"Am Heart J"},{"key":"R114-20250619","doi-asserted-by":"crossref","first-page":"e000668","DOI":"10.1161\/JAHA.113.000668","article-title":"Long-term cardiovascular risks associated with an elevated heart rate: the Framingham Heart Study.","volume":"3","author":"Ho","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"R115-20250619","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.amjcard.2014.08.042","article-title":"Relation of resting heart rate to risk for all-cause mortality by gender after considering exercise capacity (the Henry Ford exercise testing project).","volume":"114","author":"Aladin","year":"2014","journal-title":"Am J Cardiol"},{"key":"R116-20250619","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.atherosclerosis.2011.06.033","article-title":"The relationship between resting heart rate and incidence and progression of coronary artery calcification: the Multi-Ethnic Study of Atherosclerosis (MESA).","volume":"220","author":"Rubin","year":"2012","journal-title":"Atherosclerosis"},{"key":"R117-20250619","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijcard.2014.11.181","article-title":"Resting heart rate and risk of adverse cardiovascular outcomes in asymptomatic aortic stenosis: the SEAS study.","volume":"1","author":"Greve","year":"2015","journal-title":"Int J Cardiol"},{"key":"R118-20250619","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ijcard.2015.11.166","article-title":"Resting heart rate as a predictor of aortic valve stenosis progression.","volume":"1","author":"De Oliveira Moraes","year":"2016","journal-title":"Int J Cardiol"},{"key":"R119-20250619","doi-asserted-by":"crossref","first-page":"S7171","DOI":"10.1016\/j.amjcard.2017.06.012","article-title":"The nitric oxide pathway in pulmonary vascular disease.","volume":"120","author":"Klinger","year":"2017","journal-title":"Am J Cardiol"},{"key":"R120-20250619","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.yjmcc.2013.04.001","article-title":"Endothelial nitric oxide signalling regulates Notch1 in aortic valve disease.","volume":"6","author":"Bosse","year":"2013","journal-title":"J Mol Cell Cardiol"},{"key":"R121-20250619","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1152\/ajpheart.51.2008","article-title":"Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress.","volume":"295","author":"Zhou","year":"2008","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R122-20250619","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.phrs.2010.06.008","article-title":"Guanylyl cyclase activator ataciguat improves vascular function and reduces platelet activation in heart failure.","volume":"62","author":"Schafer","year":"2010","journal-title":"Pharmacol Res"},{"key":"R124-20250619","doi-asserted-by":"crossref","first-page":"e58841","DOI":"10.1371\/journal.pone.0058841","article-title":"Increased cardiac myocyte PDE5 levels in human and murine pressure overload hypertrophy contribute to adverse LV remodeling.","volume":"8","author":"Vandenwijngaert","year":"2013","journal-title":"PLoS One"},{"key":"R125-20250619","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nm1175","article-title":"Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy.","volume":"11","author":"Takimoto","year":"2005","journal-title":"Nat Med"},{"key":"R126-20250619","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.stem.2009.02.013","article-title":"Synergy between CD26\/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction.","volume":"4","author":"Zaruba","year":"2009","journal-title":"Cell Stem Cell"},{"key":"R127-20250619","first-page":"2669","article-title":"Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetologia"},{"key":"R128-20250619","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4158\/CS-2017-0153","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2018 executive summary.","volume":"26","author":"Garber","year":"2018","journal-title":"Endocr Pract"},{"key":"R129-20250619","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1161\/CIRCULATIONAHA.116.024270","article-title":"Dipeptidyl peptidase-4 induces aortic valve calcification by inhibiting insulin-like growth factor-1 signaling in valvular interstitial cells.","volume":"135","author":"Choi","year":"2017","journal-title":"Circulation"},{"key":"R130-20250619","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1136\/heartjnl-2020-317024","article-title":"Dipeptidyl peptidase-4 inhibition to prevent progression of calcific aortic stenosis.","volume":"106","author":"Lee","year":"2020","journal-title":"Heart"},{"key":"R132-20250619","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ijcard.2015.04.086","article-title":"The protective effect of GLP-1 analogue in arterial calcification through attenuating osteoblastic differentiation of human VSMCs.","volume":"189","author":"Zhan","year":"2015","journal-title":"Int J Cardiol"},{"key":"R133-20250619","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1161\/ATVBAHA.112.300278","article-title":"Cadherin-11 regulates cell-cell tension necessary for calcific nodule formation by valvular myofibroblasts.","volume":"33","author":"Hutcheson","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R134-20250619","doi-asserted-by":"crossref","first-page":"6832","DOI":"10.1021\/jm300576q","article-title":"Predicting new indications for approved drugs using a proteochemometric method.","volume":"55","author":"Dakshanamurthy","year":"2012","journal-title":"J Med Chem"},{"key":"R135-20250619","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jacbts.2018.12.003","article-title":"Celecoxib is associated with dystrophic calcification and aortic valve stenosis.","volume":"4","author":"Boweler","year":"2019","journal-title":"JACC Basic Transl Sci"},{"key":"R137-20250619","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction.","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"R138-20250619","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease.","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"key":"R139-20250619","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1611593","article-title":"Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis.","volume":"375","author":"Niessen","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000528","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T16:04:35Z","timestamp":1750349075000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,24]]},"references-count":131,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000528","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,24]]}}}